

estrogen function in ovarian cancer has some differences from that in breast cancer, and this may be a reason why Efp expression was unrelated to survival in this study.

Efp immunoreactivity was associated in the current study with the histologic type, serous adenocarcinoma. Ovarian cancer is a morphologically, histologically and biologically heterogeneous disease, which has likely contributed to difficulties in defining the molecular alterations associated with development and progression. On the basis of morphological and histologic criteria, there are four major types of primary ovarian carcinomas: serous adenocarcinoma, mucinous adenocarcinoma, endometrioid adenocarcinoma and clear cell adenocarcinoma. Some molecular studies have offered support for the hypothesis that different histologic types of ovarian carcinoma likely represent distinct disease entities. For example, serous adenocarcinomas demonstrate frequent *p53* mutations and more than 85% of mucinous ovarian adenocarcinomas show *K-ras* mutations [27,28]. Endometrioid adenocarcinomas preferentially exhibit microsatellite instability and mutations of *CTNBI* (β -catenin) [29,30]. Considering estrogenic action on ovarian cancer, which still remains controversial, it has been thought that ERs expression and its transcriptional gene expression differ in each histologic type. A higher expression of ER α relative to expression of ER β has been observed in surface epithelial ovarian cancer compared with normal ovarian surface epithelium [2,31]. As for histologic type, there is a relative paucity of ER α expression in clear cell adenocarcinoma compared with the level of expression in serous, endometrioid and mucinous adenocarcinoma [32]. In epithelial ovarian cancer, especially in serous adenocarcinoma, the germ line mutations of BRCA1 have been observed as frequently as seen in breast cancer. The BRCA1 gene has been found to inhibit signaling by ligand-activated ER α through the estrogen-responsive enhancer element and to block the transcriptional activation domain of ER α . AF-2 [33,34]. Our results, together with those of previous reports, suggest that the expression of Efp might be one of the different characteristics of each histologic type and that Efp overexpression especially correlates with serous histology, as the result of estrogen actions through ERs.

Early stages of ovarian cancer are generally asymptomatic and difficult to detect, thus, by the time clinical diagnosis made, most of patients have widespread tumor dissemination beyond the ovaries. Despite a high response rate to first-line chemotherapy, the prognosis of these women is poor, with the 5-year overall survival only 10–20% [13,22]. We need some markers of ovarian cancer to identify subpopulations of patients whose disease is progressive and behaves differently from those in the majority of patients, and which might therefore benefit from adapted therapeutic options. To our knowledge, this current report is the first to evaluated the relationships between Efp and clinicopathological parameters in epithelial ovarian cancer. In our study, the expression of Efp had no prognostic value but was related to advanced-stage disease.

Our results suggest that overexpression of Efp might cause invasive and progressive characteristics of epithelial ovarian cancer, if so Efp might have the potential to be useful as a biological marker.

The benefit of optimal surgery for patients with advanced ovarian cancer is well established [35]. Recently, Levine et al. reported that genetic differences failed to predict for outcome of surgical cytoreduction [36]. Our result that the expression of Efp did not correlate with residual tumor size after primary cytoreductive surgery is consistent with this previous report. With regard to tumor dissemination in the abdominal cavity, intrapelvic location of ovaries and their mobility in relation to adjacent structures might be in more relation to ability of optimal surgery than the genetic changes. These evidences suggest that some genetic differences including Efp expression could clarify a character of tumors but would not predict clinical outcome in epithelial ovarian cancer.

From our experimental data, the expression of Efp was detected in human epithelial ovarian cancer and correlated with ERs status, advanced-stage disease and serous adenocarcinoma histologic type. It has been suggested that the expression of Efp in human epithelial ovarian cancer relates to regulation of cell proliferation and carcinogenesis through ERs and that Efp could be a biological marker of this cancer. Further investigations are required to reveal the roles of Efp related to estrogenic action and cell-cycle regulation in epithelial ovarian cancer.

Acknowledgments

This work was supported in part by a grant-in-aid for Scientific Research from the Ministry of Health and Welfare, a grant-in-aid from the Ministry of Education, Science and Culture, a grant-in-aid from Kurokawa Cancer Research Foundation, a grant-in-aid from Japan Gynecologic Oncology Group (JGOG) and the 21st Century Center of Excellence (COE) Program Special Research Grant from the Ministry of Education Science, Sports and Culture.

References

- [1] Enmark E, Gustafsson JA. Oestrogen receptors—An overview. *J Int Med* 1999;246:133–8.
- [2] Li AJ, Baldwin RL, Karlan BY. Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. *Am J Obstet Gynecol* 2003;189:22–7.
- [3] Evans RM. The steroid and thyroid hormone receptor family. *Science* 1988;240:889–95.
- [4] Green S, Chambon P. Nuclear receptors enhance our understanding of transcription regulation. *Trends Genet* 1988;11:309–14.
- [5] Inoue S, Orimo A, Hosoi T, et al. Genomic binding-site cloning reveals an estrogen-responsive gene that encodes a RING finger protein. *Proc Natl Acad Sci U S A* 1993;99:11117–21.
- [6] Orimo A, Inoue S, Minowa O, et al. Underdeveloped uterus and reduced estrogen responsiveness in mice with disruption of the

- estrogen responsive finger protein gene, which is a direct target of estrogen receptor α . *Proc Natl Acad Sci U S A* 1999;96:12027–32.
- [7] Ikeda K, Inoue S, Orimo A, et al. Multiple regulatory elements and binding protein of the 5'-flanking region of the human estrogen-responsive finger protein (efp) gene. *Biochem Biophys Res Commun* 1997;236(3):765–71.
- [8] Orimo A, Inoue S, Ikeda K, Noji S, Muramatsu M. Molecular cloning, structure, and expression of mouse estrogen-responsive finger protein Efp. *J Biol Chem* 1995;270(41):24406–13.
- [9] Shimada N, Suzuki T, Inoue S, et al. Systemic distribution of estrogen-responsive finger protein (Efp) in human tissues. *Mol Cell Endocrinol* 2004;218:147–53.
- [10] Ikeda K, Orimo A, Higashi Y, Muramatsu M, Inoue S. Efp as a primary estrogen-responsive gene in human breast cancer. *FEBS* 2000;472:9–13.
- [11] Horie K, Urano T, Ikeda K, Inoue S. Estrogen-responsive RING finger protein controls breast cancer growth. *J Steroid Biochem Mol Biol* 2003;85:101–4.
- [12] Akahira JI, Aoki M, Suzuki T, et al. Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer. *Br J Cancer* 2004;90:2197–202.
- [13] Akahira JI, Yoshikawa H, Shimizu Y, et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. *Gynecol Oncol* 2001;81:398–403.
- [14] Akahira J, Inoue T, Suzuki T, et al. Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies. *Br J Cancer* 2000;83(11):1488–94.
- [15] Bizzi A, Codegani AM, Landoni F, et al. Steroid receptors in epithelial ovarian carcinoma: relation to clinical parameters and survival. *Cancer Res* 1988;48:6222–6.
- [16] Masood S, Heitmann J, Nuss RC, Benrubi GI. Clinical correlation of hormone receptor status in epithelial ovarian cancer. *Gynecol Oncol* 1989;34:57–60.
- [17] Rao BR, Slotman BJ. Endocrine factors in common epithelial ovarian cancer. *Endocr Rev* 1991;12:14–26.
- [18] Nitta M, Katabuchi H, Ohtake H, et al. Characterization and tumorigenicity of human ovarian surface epithelial cells immortalized by SV40 large T antigen. *Gynecol Oncol* 2001;81:10–7.
- [19] Shimizu Y, Kamo S, Amada S, et al. Toward the development of a universal grading system for ovarian epithelial carcinoma: I. Prognostic significance of histopathologic features—problems involved in the architectural grading system. *Gynecol Oncol* 1998;70:2–12.
- [20] Akahira J, Suzuki T, Ito K, et al. Differential expression of progesterone receptor isoforms A and B in the normal ovary, and in benign, borderline, and malignant ovarian tumors. *Jpn J Cancer Res* 2002;93:807–15.
- [21] McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr. Estrogen receptor analysis. *Arch Pathol Lab Med* 1985;109:716–21.
- [22] Bonnefoi H, A'Hern RP, Fisher C, et al. Natural history of stage IV epithelial ovarian cancer. *J Clin Oncol* 1999;17(3):767–75.
- [23] Munkarah AK, Hallum III AV, Morris M, et al. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. *Gynecol Oncol* 1997;64(1):13–7.
- [24] Clarke R, Skaar T, Baumann K, et al. Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression. *Breast Cancer Res Treat* 1994;31:237–48.
- [25] Lindgren P, Backstrom T, Mahlck CG, et al. Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors. *Int J Oncol* 2001;19(1):31–8.
- [26] Munstedt K, Steen J, Knauf AG, et al. Steroid hormone receptors and long term survival in invasive ovarian cancer. *Cancer* 2000;89(8):1783–91.
- [27] Anttila M, Kosma VM, Ji H, et al. Clinical significance of alpha-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer. *J Clin Oncol* 1998;16(8):2591–600.
- [28] van der Zee AG, Hollema H, Suurmeijer AJ, et al. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. *J Clin Oncol* 1995;13(1):70–8.
- [29] Aunoble B, Sanches R, Didier E, Bignon YJ. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer [review]. *Int J Oncol* 2000;16:567–76.
- [30] Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. *Histopathology* 2001;38:87–95.
- [31] Pujol P, Rey JM, Nirde P, et al. Differential expression of estrogen receptor- α and β messenger RNAs as a potential maker of ovarian carcinogenesis. *Cancer Res* 1998;58:5367–73.
- [32] Fujimura M, Hidaka T, Kataoka K, et al. Absence of estrogen receptor- α expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma. *Am J Surg Pathol* 2001;25(5):667–72.
- [33] Aida H, Takakuwa K, Nagata H, et al. Clinical features of ovarian cancer in Japanese woman with germ-line mutations of BRCA1. *Clin Cancer Res* 1998;4(1):235–40.
- [34] Fan S, Wang JA, Yuan R, et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. *Science* 1999;284:1354–6.
- [35] Chi DS, Franklin CC, Levine DA, et al. Improved optimal cytoreduction rates for stage IIIc and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. *Gynecol Oncol* 2004;94:650–4.
- [36] Levine D.A., Bonome T., Olshen A.B., et al. Gene expression profiling of advanced ovarian cancers to predict the outcome of primary surgical cytoreduction. ASCO 2004:448 [abstr 5000].

Ber-EP4 and Anti-Calretinin Antibodies: A Useful Combination for Differential Diagnosis of Various Histological Types of Ovarian Cancer Cells and Mesothelial Cells

SATOSHI OKAMOTO, KIYOSHI ITO, HIRONOBU SASANO,¹ TAKUYA MORIYA,¹ HITOSHI NIIKURA, YUKIHIRO TERADA, SHINJI SATO, KUNIHIRO OKAMURA and NOBUO YAEGASHI

Departments of Obstetrics and Gynecology, and ¹Pathology, Tohoku University School of Medicine, Sendai, Japan

OKAMOTO, S., ITO, K., SASANO, H., MORIYA, T., NIIKURA, H., TERADA, Y., SATO, S., OKAMURA, K. and YAEGASHI, N. *Ber-EP4 and Anti-Calretinin Antibodies: A Useful Combination for Differential Diagnosis of Various Histological Types of Ovarian Cancer Cells and Mesothelial Cells*. Tohoku J. Exp. Med., 2005, **206** (1), 31-40 — The differential diagnosis between reactive mesothelial cells and ovarian carcinoma cells is often difficult in cytologic specimens. Immunocytochemical procedures have been utilized in assisting this differential diagnosis, with limitations. Furthermore, previous studies examined only serous type but not other histological types of ovarian carcinoma cases. Therefore, we evaluated the practical value of various epithelial and mesothelial markers in differential diagnosis of these two types of cells. Various types of ovarian carcinoma (serous, $n = 22$; mucinous, $n = 10$; endometrioid, $n = 7$; clear cell, $n = 10$) and benign mesothelial tissues ($n = 15$) were studied by immunohistochemistry. We then studied effective panels of antibodies by immunohistochemistry in 43 cytologic specimens of ascites or peritoneal lavage fluid consisting of 20 reactive mesothelium and 23 adenocarcinomas of the ovary. In the tissue specimens, Ber-EP4, a monoclonal antibody of epithelial antigen, and a polyclonal antibody against calretinin, which is expressed in mesothelium, are used in differentiating reactive mesothelial cells from ovarian carcinoma. In cytologic specimens, the sensitivity and specificity of Ber-EP4 were 100% and 90%, respectively. The sensitivity and specificity of the anti-calretinin antibody were 90% and 91%, respectively. Using multiple regression analysis, the correlation coefficient between epithelial antigen and calretinin reactivity was $r = 0.938$, with a significance level of $p < 0.0001$. In conclusion, the combined immunostaining of cytologic specimens for Ber-EP4 and the anti-calretinin antibody is helpful for the differential diagnosis between mesothelial cells and not only serous type, but also mucinous, endometrioid and clear cell types of ovarian cancer cells. ——— peritoneal cytology; reactive mesothelial cell; ovarian carcinoma; Ber-EP4; calretinin

© 2005 Tohoku University Medical Press

Received July 6, 2004; revision accepted for publication February 10, 2005.

Correspondence: Kiyoshi Ito, M.D., Department of Obstetrics and Gynecology, Tohoku University School of Medicine, 1-1 Seiryomachi, Aoba-ku, Sendai 980-8574, Japan.

e-mail: kito@mail.tains.tohoku.ac.jp

Cytologic examination of peritoneal fluids is an important tool in detecting intraperitoneal dissemination of genital tract cancers. Ovarian cancer patients are well-known to show the highest percentage of malignant peritoneal cytology, which reflects clinical stage, intraperitoneal metastasis and patient survival (Keettel et al. 1974; Zuna and Behrens 1996). In many cases, however, the differentiation of reactive mesothelial cells (RM) from neoplasms in peritoneal fluids cannot always be made definitively on morphology alone (Fox 1993). Zuna and Behrens (1996) demonstrated that the sensitivity and specificity of cytologic examination of peritoneal fluids were 88% and 83%, respectively. Some studies have examined the criteria for distinguishing RM from adenocarcinoma cells, but the effectiveness of these criteria are limited, especially with respect to cytologic specimens (Covell et al. 1985; Mulvany 1996; Pisharodi et al. 1996; Weir and Bell 2001).

Immunohistochemical procedures have been widely utilized in aiding the differential diagnosis of numerous gynecological pathologies. However, no specific markers have been found to be diagnostic in differentiating RM from adenocarcinomas. Some of the markers that proved to be useful in separating RM from lung cancer cells have a different value in differentiating between RM and ovarian cancer cells (Ordoñez 1998). Therefore, the use of a panel of antibodies provides the highest degree of accuracy. Many studies have attempted to apply immunocytochemical staining in the differentiation of these two types of cells. However, large differences exist in the results of these published studies, regarding both the value of some of the markers and which markers should be included in the routine diagnostic panel for differentiating them (Delahaye et al. 1997; Fetsch et al. 1998; Ordoñez 1998; Lozano et al. 2001; Attanoos et al. 2002). In addition, previous studies examined only serous type but not other histological types of ovarian carcinoma cases. The aim of this investigation was to assess the practical value of markers for identifying mesothelial cells including calretinin, vascular cell adhesion molecule-1 (VCAM-1) and mesothelial cell antigen and of markers for identifying epithe-

lial cells including carcinoembryonic antigen (CEA), CA-125, cytokeratin 18, epithelial membrane antigen (EMA), epithelial related antigen and epithelial antigen in distinguishing RM from various types of ovarian cancer cells. Our findings suggest that epithelial antigen and calretinin immunoreactivity are highly effective in differentiating RM from ovarian carcinoma than other carcinoma and mesothelial markers, when employed in immunohistochemical study. We then confirmed the effectiveness of these antibodies in the immunocytochemical diagnosis of RM and ovarian cancer cells in cytologic specimens.

MATERIALS AND METHODS

Forty-nine cases of ovarian carcinoma (serous, $n = 22$; mucinous, $n = 10$; endometrioid, $n = 7$; clear cell, $n = 10$) and fifteen normal mesothelial tissues were retrieved from surgical pathology files at Tohoku University Hospital, Sendai, Japan. Clinicopathological findings for these patients were retrieved by review of patient charts. None of the patients described in this study had received preoperative chemotherapy and/or hormonal therapy or pelvic radiation. None of the patients used oral contraceptives. The lesions were classified according to the Histological Typing of Female Genital Tract Tumors by WHO (Tavassoli and Devilee 2003). All specimens were routinely processed (i.e., 10% formalin fixed for 24 to 48 hours), paraffin embedded, and thin sectioned ($3 \mu\text{m}$).

Immunohistochemical analysis was performed employing the streptavidin-biotin amplification method using a Histofine Kit (Nichirei, Tokyo), as previously described (Suzuki et al. 1994). Table 1 shows a summary of the immunomarkers used, the suppliers and specifications. All antibodies used in this study are mouse monoclonal antibodies, except for an anti-calretinin polyclonal antibody. The sections were pretreated with trypsin for Ber-EP4, proteinase K for anti-CEA, or pronase for anti-calretinin, or treated in citrate buffer at pH 6.0 in a microwave oven for 30 min for anti-CA125. The sections for MOC-31, anti-cytokeratin 18 and anti-VCAM-1 stainings were pretreated by autoclaving in citrate buffer (pH 6.0) at 121°C for 10 min. The antigen-antibody complex was visualized with 3,3'-diaminobenzidine (DAB) solution (1 mM DAB, 50 mM Tris-HCl buffer [pH 7.6], and 0.006% H_2O_2), and counterstained with hematoxylin. Suitable positive control tissues were used to confirm antibody specificity. As a negative control, nor-

TABLE 1. Characteristics of primary antibodies employed in immunohistochemistry

Antibody to:	Clone	Source	Dilution	Antigen retrieval
<i>Epithelial cell markers</i>				
Epithelial antigen	Ber-EP4	DakoCytomation*	1:25	Trypsin
EMA	E29	DakoCytomation	1:50	
Epithelial related antigen	MOC-31	DakoCytomation	1:50	Autoclave
Cytokeratin18	DC10	DakoCytomation	1:50	Autoclave
<i>Tumor markers</i>				
CA125	M11	DakoCytomation	1:20	Microwave
CEA	II-7	DakoCytomation	1:50	Proteinase K
<i>Mesothelial cell and mesothelioma markers</i>				
Mesothelial cell	HBME-1	DakoCytomation	1:50	
VCAM-1	1.4C3	DakoCytomation	1:50	Autoclave
Calretinin	-	Swant**	1:8000	Pronase

*DakoCytomation, Glostrup, Denmark ; ** Swant corp., Bellinzona, Switzerland.

EMA, epithelial membrane antigen; CEA, carcinoembryonic antigen; VCAM-1, vascular cell adhesion molecule-1.

mal rabbit or mouse IgG was used instead of the primary antibodies. No specific immunoreactivity was detected in these sections.

In addition, we examined a total of 43 cytologic specimens of ascites or peritoneal lavage fluid retrieved from the cytology files at Tohoku University Hospital, Sendai, Japan. These specimens consisted of 20 RMs and 23 adenocarcinomas of the ovaries (serous, $n = 18$; mucinous, $n = 1$; endometrioid, $n = 2$; clear cell, $n = 2$). All primary tumors were confirmed by histology. Cytologic specimens consisting of RMs were retrieved from the cases of ovarian carcinoma. The diagnoses of cytologic specimens were confirmed by board-certified cytopathologists (Sasano H. and Ito K). These cases are different from previous ones used in immunohistochemical analysis, in order to avoid bias. The collected cells obtained from ascites or peritoneal lavage fluid were fixed onto glass slides using an auto-smear method (Sakura, Inc., Tokyo). All slides were Papanicolaou-stained and reviewed to ensure that they were adequate for diagnosis. For immunocytochemistry, one representative Papanicolaou-stained smear was selected in each case and destained with 1% hydrochloric acid in 95% ethanol. We then performed all immunocytochemical procedures with primary antibodies, anti-calretinin and Ber-EP4, employing the streptavidin-biotin amplification method using a Histofine Kit. Staining was performed

following either our procedure or the procedure proposed by Dogliani et al. (1996; Okamoto 1996).

The immunostaining of tumor and/or mesothelial cells was evaluated for cytoplasmic staining. Calretinin expression was demonstrated by nuclear and cytoplasmic immunostaining. Staining for Ber-EP4 and the anti-calretinin antibody was considered positive if any number of tumor and/or mesothelial cells showed positive staining. The slides were assessed by two of the authors (K.I. and S.O.) Statistical analysis was performed using Stat View 5.0 (SAS Institute Inc., Cary, NC, USA) software. With the association between immuno-positive and -negative epithelial antigen and calretinin as explanatory variables, the judgment of whether ovarian carcinoma or mesothelial cells were detected as a dependent variable was evaluated with correlation coefficient (r) and regression equation.

RESULTS

Results of carcinoma and epithelial cell markers in 49 ovarian carcinomas and fifteen normal mesothelial tissues are summarized in Table 2. More than 90% of ovarian carcinoma cells reacted positively with epithelial antigen, EMA, epithelial related antigen and cytokeratin 18. On the other hand, EMA, epithelial related antigen and cyto-

TABLE 2. Immunoreactivity for epithelial and tumor markers in tissue specimens

	Epithelial related					
	Epithelial antigen	EMA	Antigen	CK	CA125	CEA
Serous (22)	86% (19/22)	100% (22/22)	100% (22/22)	100% (22/22)	100% (22/22)	27% (6/22)
Mucinous (10)	100% (10/10)	80% (8/10)	100% (10/10)	90% (9/10)	50% (5/10)	90% (9/10)
Endometrioid (7)	100% (7/7)	100% (7/7)	100% (7/7)	100% (7/7)	86% (6/7)	29% (2/7)
Clear (10)	90% (9/10)	100% (10/10)	100% (10/10)	100% (10/10)	100% (10/10)	10% (1/10)
Positivity (%) (Positive No./Total No.)	92% (45/49)	96% (47/49)	100% (49/49)	98% (48/49)	88% (43/49)	37% (18/49)
Normal mesothelial tissue section (15)	0% (0/15)	20% (3/15)	33% (5/15)	100% (15/15)	100% (15/15)	7% (1/15)

EMA, epithelial membrane antigen; CK, Cytokeratin 18; CEA, carcinoembryonic antigen.

keratin 18 immunoreactivities were demonstrated in 20%, 33% and 100% of mesothelial cells, respectively. Only epithelial antigen immunoreactivity was not detected in these cells.

Results of mesothelial cell markers in ovarian carcinomas and others are summarized in

Table 3. Sixty-seven to 100% of mesothelial cells demonstrated immunoreactivity of mesothelial cell antigen, VCAM-1 and calretinin. In comparison, mesothelial cell antigen, VCAM-1 and calretinin immunoreactivity was expressed in 84%, 39% and only 6% of ovarian carcinoma cells, re-

TABLE 3. Immunoreactivity for mesothelial cell and mesothelioma markers in tissue specimens

	Mesothelial antigen	VCAM-1	Calretinin
Serous (22)	100% (22/22)	68% (15/22)	5% (1/22)
Mucinous (10)	30% (3/10)	20% (2/10)	10% (1/10)
Endometrioid (7)	86% (6/7)	0% (0/7)	14% (1/7)
Clear (10)	100% (10/10)	20% (2/10)	0% (0/10)
Positivity (%) (Positive No./Total No.)	84% (41/49)	39% (19/49)	6% (3/49)
Normal mesothelial tissue section (15)	100% (15/15)	67% (10/15)	100% (15/15)




Fig. 1. Immunohistochemistry for epithelial antigen in surgical resections of: A, serous adenocarcinoma; B, mucinous adenocarcinoma; C, endometrioid adenocarcinoma; D, clear cell adenocarcinoma. Brown staining was detected in the cell membranes of all specimens. Original magnification $\times 400$.

spectively. These results suggest that epithelial antigen and calretinin immunoreactivity are highly effective in differentiating RM from ovarian carcinoma than other epithelial and mesothelial markers when employed in immunohistochemical study (Figs. 1, 2 and 3). We therefore examined the effectiveness of these antigens (epithelial antigen and calretinin) in the diagnosis of RM and ovarian carcinoma cells in cytologic specimens (Fig. 4). Immunoreactivity for epithelial antigen in cytologic specimens is summarized in Table 4. The sensitivity and specificity of Ber-EP4 in these specimens were 100% and 90%, respectively.

Immunoreactivity for calretinin in cytologic specimens is summarized in Table 5. The sensitivity and specificity of the anti-calretinin antibody in these specimens were 90% and 91%, respectively. Only two (one is serous type and another is clear cell type) of 23 ovarian carcinomas expressed immunoreactive calretinin. Using multiple regression analysis with immuno-positive and -negative epithelial antigen and calretinin as explanatory variables, and the judgment of whether ovarian carcinoma or mesothelial cells were detected as a dependent variable, we determined the correlation coefficient to be $r = 0.938$, with a significance




Fig. 2. Immunohistochemistry for epithelial antigen and calretinin in serial sections of serous ovarian carcinoma. A: Epithelial antigen immunoreactivity was predominantly detected in the cell membranes of cells. B: Calretinin immunoreactivity was negative. Original magnification $\times 400$.




Fig. 3. Immunohistochemistry for epithelial antigen and calretinin in serial sections of a normal mesothelium. A: Epithelial antigen immunoreactivity was negative. B: Calretinin immunoreactivity was detected in both the nuclei and cytoplasm. Original magnification $\times 400$.

level of $p < 0.0001$. These findings match well into an estimated multiple regression model (Table 6).

DISCUSSION

The differential diagnosis between RM and adenocarcinoma in pleural and/or peritoneal effusion continues to be a diagnostic problem in routine cytology practice. Immunocytochemistry is considered useful as a diagnostic aid in this type of differential diagnosis. To date, a significant number of antibodies have been applied to differential diagnosis of cytology specimens from pleural and/or peritoneal effusion, with various degrees of efficacy. However, the usefulness of immunocytochemistry in peritoneal cytology has been less well explored than in pleural effusions.

Studies of peritoneal immunocytochemistry with respect to the origin of ovarian carcinoma are markedly limited. Although ovarian cancer patients have the highest percentage of malignant peritoneal cytology, which represents the clinical stage, intraperitoneal metastasis and patient survival, the number of the patient specimens was small and insufficient (Khoury 1990; Ordoñez 1998a; Lozano et al. 2001; Attanoos et al. 2002). Furthermore, these studies examined only serous type but not other histological types of ovarian carcinoma cases. The differentiation of RM from ovarian carcinoma is very important for management of ovarian cancer patients. To our knowledge, the present study is the first report that summarizes data from the largest number and on various types of ovarian cancer cases demonstrat-




Fig. 4. A: Immunostaining for epithelial antigen in an ascites sample diagnosed as positive following cytodiagnosis. The cell membranes of this serous ovarian carcinoma cell are intensely stained, whereas normal mesothelial cells are negative for epithelial antigen immunostaining. B: Immunostaining for calretinin in an ascites sample diagnosed as positive following cytodiagnosis. Mesothelial cells are stained positive for calretinin, whereas ovarian carcinoma cells are negative. Original magnification $\times 400$.

ing the usefulness of immunocytochemistry in the differentiation of RM from ovarian carcinoma.

In our immunohistochemical study, epithelial antigen and calretinin were found to be effective discriminant markers in distinguishing RM from ovarian carcinomas, compared to other epithelial and mesothelial markers in surgical pathology specimens described previously (Sato et al. 2000). Ber-EP4 is a monoclonal antibody that recognizes an epitope present on 2 glycopeptides of 30 kDa and 34 kDa molecular weight, respectively (Latza et al. 1990). This recognized antigen is considered to be present in human epithelial cells and carcinomas but almost absent in the mesothelium (Latza et al. 1990; Sheibani et al. 1991; Ordoñez 1999). In 1990, Latza et al. reported epithelial antigen reactivity in 142 (98.6%) of 144 carcinomas of various organs. However, no reactivity was detected in 88 nonepithelial tumors, including 14 mesotheliomas. In another report, Sheibani and colleagues detected epithelial antigen immunoreactivity in 72 (87%) of 83 adenocarcinomas of various organs but in only one (1%) of 115 mesotheliomas (Sheibani et al. 1991). These studies appear to suggest that epithelial antigen could be of use in the differentiation of mesothelium from adenocarcinomas. According to the literature, epithelial antigen immunoreactivity depends on the primary site of the tumor (Ordoñez 1998b, 1999). Several studies have reported epithelial antigen immunoreactivity in ovarian carcinoma. Ordoñez (1998a) found that epithelial antigen reactivity was detected in all 30 serous ovarian carcinomas but in only four (11%) of 35 mesotheliomas. In addition, Attanoos et al. (2002) reported that epithelial antigen showed 95% sensitivity and 91% specificity in 32 diffuse peritoneal mesotheliomas,

TABLE 4. Immunoreactivity for epithelial antigen in cytologic specimens

	Ov. ca.	Mesothelial cell
Epithelial antigen positive (No.)	23	2
Epithelial antigen negative (No.)	0	18
Sensitivity: 100%		Specificity: 90%

Ov. ca., ovarian carcinoma cells.

TABLE 5. *Immunoreactivity for calretinin in cytologic specimens*

	Ov. ca.	Mesothelial cell
Calretinin positive (No.)	2	18
Calretinin negative (No.)	21	2
Sensitivity: 90%		Specificity: 91%
Ov. ca., ovarian carcinoma cells.		

TABLE 6. *Multiple regression analysis*

	Ov.ca.	Mesothelial cell
Epithelial antigen positive calretinin positive (No.)	2	2
Epithelial antigen positive calretinin negative (No.)	21	0
Epithelial antigen negative calretinin positive (No.)	0	17
Epithelial antigen negative calretinin negative (No.)	0	1
	23	20

Ov.ca., ovarian carcinoma cells.

The correlation coefficient between epithelial antigen and calretinin reactivity was $r = 0.938$, with a significance level of $p < 0.0001$.

20 serous papillary ovarian carcinomas and three primary peritoneal serous papillary carcinomas. Results from our present study are also consistent with these previous reports above. Epithelial antigen immunoreactivity was detected not only in serous ovarian carcinomas, but also in all mucinous, endometrioid and clear cell ovarian carcinomas.

Calretinin, which is a 29-kDa calcium-binding protein normally present in neurons of the central and peripheral nervous system, has recently been recognized as an immunohistochemical marker of reactive mesothelium and malignant mesothelioma in tissue sections (Andressen et al. 1993; Doglioni et al. 1996). In 1996, Doglioni et al. reported calretinin immunoreactivity in all of 44 mesotheliomas, but only focally in 28 (10%) of 294 adenocarcinomas of various organs including one (6%) of 16 serous papillary ovarian carci-

nomas. Ordoñez (1998a), who used a different commercial antibody, reported that all 35 mesotheliomas demonstrated calretinin expression, whereas only three (10%) of 30 serous papillary ovarian carcinomas expressed calretinin immunoreactivity. The distribution of calretinin immunoreactivity has recently been suggested to be useful as the only nuclear reactivity marker that is highly specific for the mesothelium (Cury et al. 2000; Attanoos et al. 2002). These studies demonstrated rates of immunoreactivity for normal and neoplastic mesothelium ranging from 80% to 100%, with only rare adenocarcinomas exhibiting nuclear immunoreactivity. Interpreting only nuclear immunoreactivity as being unequivocally positive, a study by Attanoos et al. (2002) recently reported that calretinin was identified as the most sensitive (88%) and specific (100%) mesothelial marker in the distinction of peritoneal mesothelioma from

serous papillary ovarian carcinoma with.

CEA has been widely applied in immunohistochemistry due to its ability to distinguish adenocarcinomas from reactive and neoplastic mesothelium. Although CEA is considered to be highly specific, it has a relatively low sensitivity in serous ovarian carcinomas (Brown et al. 1997; Ordoñez 1998a). Our findings were consistent with those previous reports. Results from our study described the immuno-reactive expression of immunoreactivity of epithelial related antigens, cytokeratin 18, EMA and CA125 in the great majority of ovarian carcinomas and mesothelial tissues, a finding consistent with previous reports (Delahaye et al. 1991, 1997; Bateman et al. 1997; Ordoñez 1998a; Attanoos et al. 2002). These results suggest that these markers are not necessarily helpful in distinguishing adenocarcinomas of the ovary from a reactive and/or neoplastic mesothelium. VCAM-1 is a cytokine-induced adhesion molecule which recognizes ligands that are abundantly present on leukocytes. Ruco et al. (1996) recently reported that VCAM-1 was detected in 14 of 16 malignant mesotheliomas and in only one of 58 epithelial malignant tumors. However, in our study, VCAM-1 was expressed in ovarian carcinomas, especially in the serous papillary type. HBME-1 was generated using a suspension of human mesothelioma cells from patients diagnosed with malignant epithelial mesothelioma. No mesothelial antigen reactivity has been detected in normal cells other than mesothelial cells, but this antibody has been reported to react with adenocarcinomas in some organs (Fetsch and Abati 2001). Our results have confirmed that mesothelial antigen immunostaining has no practical value in distinguishing between these two tumors.

From our findings we conclude that epithelial antigen and calretinin are useful discriminant markers in the mesothelia for not only serous but also mucinous, endometrioid and clear cell types of ovarian carcinomas. We also examined the effectiveness of these antibodies (Ber-EP4, anti-calretinin) in the diagnosis of mesothelial cells and ovarian cancer cells in cytologic specimens. Immunocytochemical results from the present

study suggest that the combined immunostaining for Ber-EP4 and the anti-calretinin antibody is helpful for the differential diagnosis between mesothelial cells and not only serous type, but also mucinous, endometrioid and clear cell types of ovarian cancer cells in cytologic specimens.

References

- Andressen, C., Blumcke, I. & Celio, M.R. (1993) Calcium-binding proteins: selective markers of nerve cells. *Cell Tissue Res.*, **271**, 181-208.
- Attanoos, R.L., Webb, R., Dojcinov, S.D. & Gibbs, A.R. (2002) Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. *Histopathology*, **40**, 237-244.
- Bateman, A.C., al-Talib, R.K., Newman, T., Williams, J.H. & Herbert, A. (1997) Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression. *Histopathology*, **30**, 49-56.
- Brown, R.W., Campagna, L.B., Dunn, J.K. & Cagle, P.T. (1997) Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. *Am. J. Clin. Pathol.*, **107**, 12-19.
- Covell, J.L., Carry, J.B. & Feldman, P.S. (1985) Peritoneal washings in ovarian tumors. Potential sources of error in cytologic diagnosis. *Acta Cytol.*, **29**, 310-316.
- Cury, P.M., Butcher, D.N., Fisher, C., Corrin, B. & Nicholson, A.G. (2000) Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. *Mod. Pathol.*, **13**, 107-112.
- Delahaye, M., Van der Ham, F. & Van der Kwast, T.H. (1997) Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions. *Diagn. Cytopathol.*, **17**, 115-120.
- Delahaye, M., Hoogsteden, H.C. & Van der Kwast, T.H. (1991) Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma. *J. Pathol.*, **165**, 137-143.
- Dogliani, C., Dei Tos, A.P., Laurino, L., Iuzzolino, P., Chiarelli, C., Celio, M.R. & Viale, G. (1996) Calretinin: A novel immunocytochemical marker for mesothelioma. *Am. J. Surg. Pathol.*, **20**, 1037-1046.
- Fetsch, P.A., Abati, A. & Hijazi, Y.M. (1998) Utility of the Antibodies CA19-9, HBME-1, and Thrombomodulin In the Diagnosis of Malignant Mesothelioma and Adenocarcinoma in Cytology. *Cancer Cytopathol.*, **84**, 101-108.
- Fetsch, P.A. & Abati, A. (2001) Immunocytochemistry in effusion cytology: a contemporary review. *Cancer*, **93**, 293-308.
- Fox, H. (1993) Primary neoplasia of the female peritoneum. *Histopathology*, **23**, 103-110.
- Keettel, W.C., Pixley, E.E. & Buchsbaum, H.J. (1974) Experience with peritoneal cytology in the management of gynecologic malignancies. *Am. J. Obstet. Gynecol.*, **120**, 174-182.
- Khoury, N., Raju, U., Crissman, J.D., Zarbo, R.J. &

- Greenawald, K.A. (1990) A comparative immunohistochemical study of peritoneal and ovarian serous tumors, and mesotheliomas. *Hum. Pathol.*, **21**, 811-819.
- Latza, U., Niedobitek, G., Schwarting, R., Nekarda, H. & Stein, H. (1990) Ber-EP4: New monoclonal antibody which distinguishes epithelia from mesothelia. *J. Clin. Pathol.*, **43**, 213-219.
- Lozano, M.D., Panizo, A., Toledo, G.R., Sola, J.J. & Pardo-Mindan, J. (2001) Immunocytochemistry in the differential diagnosis of serous effusions. *Cancer Cytopathol.*, **93**, 68-72.
- Mulvany, N. (1996) Cytohistologic correlation in malignant peritoneal washings. Analysis of 75 malignant fluids. *Acta Cytol.*, **40**, 1231-1239.
- Okamoto, S., Konno, R., Takano, T., Wagatsuma, S., Nagase, S., Yoshida, Y., Igarashi, T., Sato, S. & Yajima, A. (1998) Immunohistochemistry as a method of differential diagnosis between malignant ovarian tumors cells and mesothelial cells in ascites. *J. Jpn. Soc. Clin. Cytol.*, **37**, 389-393. (in Japanese with English abstract)
- Ordoñez, N.G. (1998a) Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. *Am. J. Surg. Pathol.*, **22**, 1203-1214.
- Ordoñez, N.G. (1998b) Value of Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature. *Am. J. Clin. Pathol.*, **109**, 85-89.
- Ordoñez, N.G. (1999) Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. *Am. J. Clin. Pathol.*, **112**, 75-89.
- Pisharodi, L.R. & Bedrossian, C.W.M. (1996) Cytopathology of serous neoplasia of the ovary and the peritoneum: differential diagnosis from mesothelial proliferations. *Diagn. Cytopathol.*, **15**, 292-295.
- Ruco, L.P., de Laat, P.A., Matteucci, C., Bernasconi, S., Sciacca, F.M., Van der Kwast, T.H., Hoogsteden, H.C., Uccini, S., Mantovani, A. & Versnel, M.A. (1996) Expression of ICAM-1 and VCAM-1 in human malignant mesothelioma. *J. Pathol.*, **179**, 266-271.
- Sato, S., Okamoto, S., Ito, K., Konno, R. & Yajima, A. (2000) Differential diagnosis of mesothelial and ovarian cancer cells in ascites by immunocytochemistry using Ber-EP4 and calretinin. *Acta Cytol.*, **44**, 485-487.
- Sheibani, K., Shin, S.S., Kezirian, J. & Weiss, L.M. (1991) Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma. *Am. J. Surg. Pathol.*, **15**, 779-784.
- Suzuki, T., Sasano, H., Kimura, N., Tamura, M., Fukaya, T., Yajima, A. & Nagura, H. (1994) Immunohistochemical distribution of progesterone, androgen and oestrogen receptors in the human ovary during the menstrual cycle: relationship to expression of steroidogenic enzymes. *Human Reprod.*, **9**, 1589-1595.
- Tavassoli, F.A. & Devilee, P. (2003) Pathology and genetics of tumours of the breast and female genital organs. In: *World Health Organization Classification of Tumours*, World Health Organization, Lyon, pp. 113-145.
- Weir, M.M. & Bell, D.A. (2001) Cytologic identification of serous neoplasms in peritoneal fluids. *Cancer Cytopathol.*, **93**, 309-318.
- Zuna, R.E. & Behrens, A. (1996) Peritoneal washing cytology in gynecologic cancers: long-term follow-up of 355 patients. *J. Natl. Cancer Inst.*, **88**, 980-987.